Customized ablations following IOL implantation = spectacle independence

Article

Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence.

Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence, according to Michael Knorz from the University Hospital, Mannheim, Germany.

Dr Knorz bilaterally implanted multifocal IOLs (Tecnis aspheric MF or ReZoom; AMO) into 14 patients with hyperopia and astigmatism of more than 2 D. A femtosecond-laser flap (IntraLase FS-60) of 100 microns and 9 mm was created immediately prior to lens surgery without lifting it. In eyes implanted with the Tecnis lens, a wavefront-guided ablation was performed, meanwhile in eyes implanted with the ReZoom lens, a standard ablation was performed with the Visx Star S4 (AMO) to fine tune the refraction.

Following implantation of the IOLs, average sphere was +0.85 and average cylinder was +1.04. After laser enhancement, sphere was +0.12 and cylinder +0.23. Higher order aberrations decreased significantly from 0.6 after IOL implantation to 0.32 after laser correction. No patient required spectacles postoperatively.

Dr Knorz believes that customized ablations following IOL implantation allows most patients to achieve spectacle independence and decreases the incidence of higher order aberrations.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.